LHDX 0.00 Lucira Health, Inc.
| Range: | 0.108-4.35 | Vol Avg: | 21451802 | Last Div: | 0 | Changes: | 0 |
| Beta: | 3.76 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Feb 04 2021 | Empoloyees: | 221 | ||
| CUSIP: | 54948U105 | CIK: | 0001652724 | ISIN: | US54948U1051 | Country: | US |
| CEO: | Mr. Erik T. Engelson | Website: | https://www.lucirahealth.com | ||||
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow